| Literature DB >> 35253352 |
Jacquelyn N Crane1, Wei Xue2, Amira Qumseya2, Zhengya Gao2, Carola A S Arndt3, Sarah S Donaldson4, Douglas J Harrison5, Douglas S Hawkins6, Corinne M Linardic7, Leo Mascarenhas8, William H Meyer9, David A Rodeberg10, Erin R Rudzinski11, Barry L Shulkin12, David O Walterhouse13, Rajkumar Venkatramani14, Aaron R Weiss15.
Abstract
The Children's Oncology Group (COG) uses Clinical Group (CG) and modified Tumor Node Metastasis (TNM) stage to classify rhabdomyosarcoma (RMS). CG is based on surgicopathologic findings and is determined after the completion of initial surgical procedure(s) but prior to chemotherapy and/or radiation therapy. The modified TNM stage is based on clinical and radiographic findings and is assigned prior to any treatment. These systems have evolved over several decades. We review the history, evolution, and rationale behind the current CG and modified TNM classification systems used by COG for RMS. Data from the seven most recently completed and reported frontline COG trials (D9602, D9802, D9803, ARST0331, ARST0431, ARST0531, ARST08P1) were analyzed, and confirm that CG and modified TNM stage remain relevant and useful for predicting prognosis in RMS. We propose updates based on recent data and discuss factors warranting future study to further optimize these classification systems.Entities:
Keywords: clinical group; rhabdomyosarcoma; stage
Mesh：
Year: 2022 PMID： 35253352 PMCID： PMC9233945 DOI： 10.1002/pbc.29644
Source DB: PubMed Journal: Pediatr Blood Cancer ISSN： 1545-5009 Impact factor: 3.838